The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer

European Journal of Cardio-thoracic Surgery

Volumn 44, Issue 1, 2013, Pages 83-87

  Miyasaka, Yoshikazu ^a   Suzuki, Kenji ^a   Takamochi, Kazuya ^a   Matsunaga, Takeshi ^a   Oh, Shiaki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fluorodeoxyglucose positron emission tomography; Non small cell lung cancer; Pathological nodal involvement

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LOBECTOMY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MEDIASTINUM LYMPH NODE; MEDICAL HISTORY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SMOKING;

FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY; NON-SMALL-CELL LUNG CANCER; PATHOLOGICAL NODAL INVOLVEMENT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 84879565229     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs604     Document Type: Article

References (25)

1. Konishi J, Yamazaki K, Tsukamoto E, Tamaki N, Onodera Y, Otake T et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003;70:500-6.
2. Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E, et al. Pattern and predictors of occult mediastinal lymph node involvement in nonsmall cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg 2008;33:104-9.
3. Melek H, Gunluoglu MZ, Demir A, Akin H, Olcmen A, Dincer SI. Role of positron emission tomography in mediastinal lymphatic staging of nonsmall cell lung cancer. Eur J Cardiothorac Surg 2008;33:294-9.
4. Carnochan FM, Walker WS. Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients. Eur J Cardiothorac Surg 2009;35:781-4; discussion 84-5.
5. Suzuki K, Koike T, Asakawa T, Kusumoto M, Asamura H, Nagai K, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer ( Japan Clinical Oncology Group 0201). J Thorac Oncol 2011;6:751-6.
6. Suzuki K, Kusumoto M, Watanabe S, Tsuchiya R, Asamura H. Radiologic classification of small adenocarcinoma of the lung: radiologic-pathologic correlation and its prognostic impact. Ann Thorac Surg 2006;81:413-9.
7. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9.
8. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-60.
9. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
10. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Lukanich JM, Mentzer SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000;70:1826-31.
11. De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007;32:1-8.
12. Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005;47:235-42.
13. Gomez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M, Gimferrer JM, et al. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. Eur J Cardiothorac Surg 2010;37:1168-74.
14. Tasci E, Tezel C, Orki A, Akin O, Falay O, Kutlu CA. The role of integrated positron emission tomography and computed tomography in the assessment of nodal spread in cases with non-small cell lung cancer. Interact CardioVasc Thorac Surg 2010;10:200-3.
15. Sanli M, Isik AF, Zincirkeser S, Elbek O, Mete A, Tuncozgur B, et al. Reliability of positron emission tomography-computed tomography in identification of mediastinal lymph node status in patients with nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2009;138:1200-5.
16. Fischer BM, Mortensen J, Hansen H, Vilmann P, Larsen SS, Loft A, et al. Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax 2011; 66:294-300.
17. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1-3 cm), and large (>3 cm) lymph node lesions. Chest 2000;117:773-8.
18. McCann J. New techniques catch lung cancers earlier. J Natl Cancer Inst 1997;89:1838-9.
19. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41: 1369-79.
20. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348: 2500-7.
21. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-9.
22. Takamochi K, Nagai K, Yoshida J, Suzuki K, Ohde Y, Nishimura M, et al. Pathologic N0 status in pulmonary adenocarcinoma is predictable by combining serum carcinoembryonic antigen level and computed tomographic findings. J Thorac Cardiovasc Surg 2001;122:325-30.
23. Takamochi K, Nagai K, Suzuki K, Yoshida J, Ohde Y, Nishiwaki Y. Clinical predictors of N2 disease in non-small cell lung cancer. Chest 2000;117: 1577-82.
24. Takamochi K, Yoshida J, Nishimura M, Yokose T, Sasaki S, Nishiwaki Y, et al. Prognosis and histologic features of small pulmonary adenocarcinoma based on serum carcinoembryonic antigen level and computed tomographic findings. Eur J Cardiothorac Surg 2004;25:877-83.
25. Casiraghi M, Travaini LL, Maisonneuve P, Tessitore A, Brambilla D, Agoglia BG, et al. Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria?. Eur J Cardiothorac Surg 2011;39:e38-43.